Literature DB >> 8843313

Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.

L M Ednie1, M A Visalli, M R Jacobs, P C Appelbaum.   

Abstract

Activities of clarithromycin, erythromycin, and azithromycin against 120 pneumococci from the United States were tested by agar dilution MIC. All three compounds yielded MICs at which 90% of the isolates were inhibited (MIC90S) of < or = 0.125 micrograms/ml against penicillin-susceptible and -intermediate strains, but MIC90S against resistant strains were > 128.0 micrograms/ml. All erythromycin-resistant strains were also resistant to clarithromycin and azithromycin. Clarithromycin yielded MICs which were generally one or two dilutions lower than those of the other two compounds for all strains. The respective bacteriostatic and bactericidal values (micrograms per milliliter) for two susceptible, two intermediate, and two resistant strains were 0.004 to 0.03 and 0.016 to 0.03 (0.004 to 0.03/0.016 to 0.03) (clarithromycin), 0.008 to 0.06/0.016/0.016 to 0.125 (erythromycin), and 0.016 to 0.06/0.03 to 0.125 (azithromycin); clarithromycin yielded the lowest values. All compounds were uniformly bactericidal after 24 h only; erythromycin was bactericidal at eight times the MIC, and azithromycin and clarithromycin were both bactericidal at two time the MIC. The relevance of these in vitro differences requires clarification by clinical trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843313      PMCID: PMC163449     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 3.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

5.  Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment.

Authors:  C T Nelson; E O Mason; S L Kaplan
Journal:  Pediatr Infect Dis J       Date:  1994-07       Impact factor: 2.129

Review 6.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

7.  Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae.

Authors:  R Muñoz; T J Coffey; M Daniels; C G Dowson; G Laible; J Casal; R Hakenbeck; M Jacobs; J M Musser; B G Spratt
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

8.  In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

Authors:  A L Barry; M A Pfaller; P C Fuchs; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use.

Authors:  E O Mason; S L Kaplan; L B Lamberth; J Tillman
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  9 in total
  9 in total

1.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

2.  Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis       Date:  2002-01

3.  Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae.

Authors:  J H Jorgensen; J M Swenson; F C Tenover; A Barry; M J Ferraro; P R Murray; L B Reller
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

5.  Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.

Authors:  R Dagan; E Leibovitz; D M Fliss; A Leiberman; M R Jacobs; W Craig; P Yagupsky
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 6.  Choosing the right macrolide antibiotic. A guide to selection.

Authors:  L Charles; J Segreti
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 7.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

8.  In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.

Authors:  G A Pankuch; S A Jueneman; T A Davies; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Hematuria in a 3-month-old filly with an internal umbilical abscess and internal iliac artery aneurysm.

Authors:  Luiza Zakia; Sarah Shaw; Natacha Bonomelli; Siobhan O'Sullivan; Alex Zur Linden; Marie Dubois; John Baird; Bruce Guest
Journal:  Can Vet J       Date:  2021-08       Impact factor: 1.008

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.